Pharmacokinetics and Pharmacodynamics of Biological Drugs
Syllabus, Master's level, 3FB037
- Code
- 3FB037
- Education cycle
- Second cycle
- Main field(s) of study and in-depth level
- Drug Discovery and Development A1N, Pharmaceutical Sciences A1N
- Grading system
- Fail (U), Pass (G), Pass with distinction (VG)
- Finalised by
- The Educational Board of Pharmacy, 15 September 2022
- Responsible department
- Department of Pharmacy
Entry requirements
150 credits which of 120 credits in biomedicine, biology, pharmaceutical science, chemistry and/or science/engineering. Prior studies should contain 7.5 credits in pharmacokinetics and 7.5 credits in pharmacology. Proficiency in English equivalent to the Swedish upper secondary course English 6.
Learning outcomes
On completion of the course, the student will be able to
- Explain principles for distribution and elimination of different types of biological drugs and their relation to desired and unwanted effects
- Interpret results from pharmacokinetic-pharmacodynamic (PKPD) studies of monoclonal antibodies
- Describe challenges specific to characterize pharmacokinetics and pharmacodynamics (PKPD) for biological drugs in different therapeutic areas
- Plan and motivate the design of clinical trials of biological drugs based on pharmacokinetic and pharmacodynamic (PKPD) aspects
- Identify PKPD properties of relevance to biosimilars
- Summarize and structure results from a scientific literature review
- Communicate scientific results for both lay people and expert groups in proper English
- Argue for a PKPD-related hypothesis based on scientific documentation
Content
The course provides a detailed view of PK and PD properties for different biological drugs and illustrates how these properties affect both drug development and use. The course focuses on protein drugs, especially monoclonal antibodies, but also covers other types of biological drugs such as peptides, oligonucleotides, bispecific antibodies, antibody conjugates, hormones, enzymes, vaccines and cell therapies. The course is divided into five modules that include PK (PD) with a focus on mAbs (1 credits) and other biological drugs (1 credits), therapy area-specific aspects (0.5 credits), translation from preclinic to clinic and clinical drug development (2 credits) and biosimilars (0.5 credits).
Instruction
The main part of the work takes place in groups. The teaching consists of lectures, workshops, and demonstrations/exercises with software. Each workshop is a larger assignment that is reported joint in groups or presented in writing individually. Compulsory parts of the course: Active participation in workshops.
Assessment
The course uses a combination of continuous examinations and a written final exam. The course is divided into five modules that are examined through oral presentations (2 as 0.5 hp, 2 as 1 hp) as well as oral and written assignment (1 as 2 hp). The written exam is credited with 2.5 hp.
If there are special reasons for doing so, an examiner may make an exception from the method of assessment indicated and allow a student to be assessed by another method. An example of special reasons might be a certificate regarding special pedagogical support from the disability coordinator of the university. Re-examination is organised when necessary.
Reading list
No reading list found.